|
 |
AggrastatThis page contains recent news articles, when available, and an overview of Aggrastat but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Aggrastat (when available) Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. When administered intravenously, tirofiban inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. When given according to the recommended regimen, >90% inhibition is attained by the end of the 30-minute infusion. Tirofiban has been recently shown in patients with unstable angina to reduce ischemic events at 48 hours following infusion when compared to standard heparin therapy. For treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy. Mechanism Of Action: Tirofiban is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation. Platelet aggregation inhibition is reversible following cessation of the infusion of Tirofiban. News Articles on Tirofiban New Management Hires for Burnham Aimed at Accelerating Commercialization Efforts - Oct 22, 2009 Burnham's pipeline includes three drugs that have already won FDA approval — heart attack medicines Integrilin and Aggrastat, and the cancer drug Targretin. ... GenomeWeb Daily News Medicure Appoints Eric Johnstone As CFO - Quick Facts - Nov 2, 2009 ...(RTTNews) - Medicure Inc. (MPH.TO: News ) announced the appointment of Eric Johnstone as Chief Financial Officer of the Company effective November 1. ... RTT News Merck Announces Third-Quarter 2009 Financial Results - Oct 22, 2009 ...a $300 million expense for a contribution to The Merck Company Foundation, a $249 million gain on the company's remaining worldwide rights to AGGRASTAT, ... Reuters Medicure Reaches Agreement With Lender Under Its Secured Debt ... - Aug 14, 2009 The company said that it is continuing work to improve overall financial performance and to further refine its commercial strategy for AGGRASTAT. by RTT RTT News Medicure Announces Agreement With Secured Lender - Aug 16, 2009 Management is continuing work to improve overall financial performance and to further refine its commercial strategy for AGGRASTAT ® . PR-USA.net (press release) aggrastat, tramadol, anafranil and genuine. - Jun 30, 2009 Our aggfastat of view aggrastzt prescription aggrastat gradually means for sexual oversymbolization in love. Whether aggrastat Tabs view commonly erotic На плувка и дъно Clavis Turns Good Data into $20M Placement - Jun 26, 2009 ...and are expected to provide management with additional resources to refine its strategy regarding the development of Aggrastat and MC-1/Avastrem. BioWorld Online Medicure Announces Private Placement - Jun 26, 2009 The Company's primary business activity is the marketing and distribution of AGGRASTAT ® (tirofiban hydrochloride) in the United States for acute coronary PR-USA.net (press release) Timing of anti-blood clot drug shown flexible in study - Mar 30, 2009 Newby noted that a similar anti-platelet medicine called Aggrastat (tirofiban) is also used during angiograms, but cautioned that findings for Integrilin Reuters Medicure Announces Regulatory Approval of a Phase II Clinical ... - Mar 11, 2009 The Company's primary business activity is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) in the United States for acute coronary MSNBC Medicure Announces Second Quarter Fiscal 2009 Financial Results - Jan 13, 2009 Net revenue from the sale of AGGRASTAT® for the second quarter of fiscal 2009 increased 25% over the net revenue for the previous quarter and by 350% MSNBC Medicure Launches New Clinical Program - Jan 12, 2009 Dr. Friesen noted that, "While Medicure's primary focus remains the continued growth of AGGRASTAT(R) sales through its US marketing subsidiary, FOXBusiness What treatments work for unstable angina? - Jan 21, 2009 There are three of them: abciximab (brand name ReoPro), eptifibatide (Integrilin) and tirofiban (Aggrastat). More... Direct thrombin inhibitors: These drugs guardian.co.uk, Merck Announces Fourth-Quarter and Full-Year 2008 Financial Results - Feb 3, 2009 ...a $300 million expense for a contribution to the Merck Company Foundation, a $249 million gain on the Company's remaining worldwide rights to AGGRASTAT, Trading Markets (press release), Symmetrix Pharmaceuticals Announces the Appointment of Ronald J ... - Dec 23, 2008 ...and development effort which culminated in the identification and eventual FDA approval of the anti-platelet GPIIb/IIIa antagonist, Aggrastat(R). PR Newswire (press release), Medicure Repays $12 Million Senior Debt - Nov 3, 2008 ...and including Silicon Valley Bank and Oxford Finance Corporation, to finance Medicure's acquisition of the US marketing rights to AGGRASTAT(R). FOXBusiness Medicure Announces First Quarter Fiscal 2009 Financial Results - Oct 14, 2008 Net revenue from the sale of AGGRASTAT(R) for the first quarter of fiscal 2009 increased 58% over the net revenue for the previous quarter and by 144% MarketWatch Junior explorer soars on diamond report - Oct 15, 2008 Medicure (TSX: T.MPH, Stock Forum), after Tuesday's closing bell, said net revenue from the sale of AGGRASTAT for the first quarter of fiscal 2009 increased Stockhouse, Biopharma co reports revenue surge - Oct 14, 2008 Medicure (TSX: T.MPH, Stock Forum), after Tuesday’s closing bell, said net revenue from the sale of AGGRASTAT for the first quarter of fiscal 2009 increased Stockhouse, Medicure Inc.: New Data Shows AGGRASTAT Offers Significant ... Sep 3, 2008 The data comes from a double-blinded study of AGGRASTAT(R) entitled the 3T/2R Study (Tailoring Treatment with Tirofiban in patients showing Resistance toMarketWatch Aggrastat cuts heart attack risk after angioplasty Sep 2, 2008 The latest results with Aggrastat, which is sold by Medicure (MPH.TO: Quote, Profile, Research, Stock Buzz) in the United States and by IrokoReuters Robust Sales of Integrilin, ReoPro and Aggrastat Will Drive the ... Sep 9, 2008 The new Pharmacor report Acute Coronary Syndrome: UA/NSTEMI finds that antiplatelet agents such as Integrilin, ReoPro and Aggrastat form a criticalEarthtimes (press release), New Data Shows Acute Heart Attack Patients Given AGGRASTAT® in ... Sep 1, 2008 Early, in–ambulance treatment with antiplatelet medicine AGGRASTAT ® (tirofiban HCL), in addition to the standard combined treatment of aspirin,elEconomista.es, Medicure Reports Financial Results for Fiscal 2008 Aug 28, 2008 The Company further advised that its primary focus would shift to increasing the sales of AGGRASTAT(R) through its commercial business and that theFOXBusiness Study supports in-ambulance STEMI treatment Sep 1, 2008 Data from the Ongoing Tirofiban in Myocardial Infarction Evaluation (On-TIME) 2 trial in showed that treatment with AGGRASTAT - a glycoprotein IIb/IIIaPharmacy Europe, Medicure post '08 loss from continuing operations of $57.4 million Aug 28, 2008 For the year ended May 31, Medicure posted revenues of $2.2 million from its commercial asset Aggrastat, down from $5.9 million in 2007.660 News, Adding tirofiban in aspirin/clopidogrel nonresponders cuts ... Sep 3, 2008 Munich, Germany - Giving tirofiban (Aggrastat, Medicure Pharma) during elective PCI to patients who demonstrate aspirin and/or clopidogrel resistance canTheHeart.Org, Fish oil beats Crestor for heart failure Sep 2, 2008 Using Merck's antiplatelet drug Aggrastat in patients with a certain type of heart attack--in addition to the standard combo of aspirin, heparin,FiercePharma, Canadian small/micro-cap weekend roundup Aug 30, 2008 AGGRASTAT blocks the aggregation of platelets via fibrinogen, thereby reducing thrombus burden and improving blood supply to ischemic myocardium.Stockhouse, Junior explorer soars on gold results Sep 3, 2008 ...said that new data presented at the annual European Society of Cardiology Congress in Munich, Germany showed AGGRASTAT (tirofiban HCL) significantlyStockhouse, Biopharma stock pops on data Sep 3, 2008 Stock Forum) Wednesday said that new data presented at the annual European Society of Cardiology Congress in Munich, Germany showed AGGRASTAT (tirofibanStockhouse, Neue Daten zeigen, dass das gerinnungshemmende Medikament ... Sep 2, 2008 Eine Patientengruppe wurde zusätzlich zur Standardtherapie mit Aspirin und Clopidogrel mit AGGRASTAT ® behandelt, die andere mit einem Placebopräparat.Business Wire (press release), Neue Daten belegen, dass ambulant und unter Einhaltung der ... Aug 30, 2008 1 Eine mittlere 60-minütige Prä-PCI-Verabreichung von AGGRASTAT ® im Ambulanz- oder Überweisungszentrum reduzierte die kumulative ST-Segment-Abweichung vorBusiness Wire (press release), Nieuwe data toont aan dat anti-stollingsmedicijn AGGRASTAT het ... Sep 2, 2008 PHILADELPHIA--(BUSINESS WIRE)--Anti-bloedstollingsmedicijn, AGGRASTAT(R) (tirofiban HCL), een glycoproteïne IIb/IIIa remmer, heeft een significant lagerBusiness Wire (press release), Empresas.- 'Aggrastat' (Merck) reduce la incidencia de infartos ... Sep 2, 2008 El antiagregante plaquetario tirofiban HCL, registrado como 'Aggrastat' por los laboratorios Merck, ha demostrado "reducir considerablemente" la incidenciaecodiario, Nieuwe data wijst uit dat het toedienen van Aggrastat aan ... Sep 1, 2008 PHILADELPHIA, Pennsylvania--(BUSINESS WIRE)--Vroegtijdige behandeling in de ambulance met AGGRASTAT(R) (tirofiban HCL), een geneesmiddel tegenBusiness Wire (press release), Nuevos datos demuestran que la administración en la ambulancia de ... Aug 30, 2008 ...(BUSINESS WIRE)--Un tratamiento previo, en la ambulancia, con el antiagregante plaquetario AGGRASTAT ® (tirofiban HCL), como complemento al tratamientoBusiness Wire (press release), PHILADELPHIE -- (BUSINESS WIRE) Sep 2, 2008 Les patients ont été traités, de manière randomisée et en double aveugle, par AGGRASTAT ® ou par placebo, en plus de la thérapie ordinaire à base d'AspirineBoursier.com (Communiqués de presse), Revue de presse Sep 1, 2008 AGGRASTAT®, un inhibiteur de la glycoprotéine membranaire IIb/IIIa, est indiqué dans la prévention de l'infarctus du myocarde précoce chez les patientsInformationHospitaliere.com, PHILADELPHIE, Pennsylvanie -- (BUSINESS WIRE) Aug 30, 2008 2 On-TIME 2 est la toute première étude menée pour évaluer l'efficacité et l'innocuité d'AGGRASTAT ® , un agent qui appartient à la classe des inhibiteursBoursier.com (Communiqués de presse), Tirofiban HCL reduce la incidencia de ataque al corazón tras una ... Sep 8, 2008 Tirofiban HCL —comercializado por Iroko como Aggrastat— ha demostrado reducir considerablemente la incidencia de ataque al corazón tras una angioplastiaGaceta Médica, Nuovi dati mostrano che la somministrazione in ambulanza di ... Aug 30, 2008 Il trattamento precoce in ambulanza a base del farmaco anti-aggregante piastrinico AGGRASTAT(R) (tirofiban HCL), associato alla terapia concomitanteWall Street Italia, Medicure Provides Corporate Update - Jul 22, 2008 ..."I am pleased that the Company has been able to reduce its expenses while still preserving and seeing some positive signs in its AGGRASTAT® business," Earthtimes (press release), Merck Reports Second-Quarter 2008 Financial Results - Jul 21, 2008 ...a $300 million expense for a contribution to The Merck Company Foundation, a $249 million gain on the Company's remaining worldwide rights to AGGRASTAT MarketWatch Don't be so sniffy about Dr Snake - Jun 17, 2008 Aggrastat is a super aspirin that prevents blood clots, as some snakebite victims bleed to death because the venom contains anti-clotting proteins. Asia Times Online, Medicure Comments on Positive AGGRASTAT Results Presented at the ... - Apr 3, 2008 ..."We are very pleased with the positive data presented on AGGRASTAT® at ACC," commented Medicure's President and CEO, Albert D. Friesen, PhD. CNNMoney.com Medicure Announces Third Quarter Fiscal 2008 Financial Results - Apr 14, 2008 During the third quarter of fiscal 2008, sales of AGGRASTAT® improved over the prior quarterly results by $379000 but were lower as compared to the same CNNMoney.com High-dose tirofiban as effective as abciximab in reducing ST ... - Mar 31, 2008 AGGRASTAT is not currently approved for use in STEMI patients or as adjunctive therapy in patients undergoing percutaneous coronary intervention (PCI). EurekAlert (press release), Medicure Inc. rises more than 50% on positive tirofiban studies - Apr 4, 2008 ..."We are very pleased with the positive data presented on Aggrastat," commented Medicure's president and CEO, Albert D. Friesen. Medicure shares fell about National Post, Merck Profit Gains on New Drugs, Partnership Payment (Update3) - Apr 21, 2008 The company also posted a $249 million gain from the sale of its anticoagulant drug Aggrastat to Iroko Pharmaceuticals. Sales of cholesterol medicines Bloomberg Tirofiban can be used to treat STEMI, study shows - Apr 1, 2008 Tirofiban, manufactured under the trade name Aggrastat by MSD, is only currently licensed in the UK for use in treatment of non-STEMI patients. Nursing Times, Search By Symbol - Apr 21, 2008 Other income in the quarter was $2.18 billion, including a $249 million gain on Merck's divestiture of its remaining worldwide rights to AGGRASTAT to Iroko RTT News, Tirofiban Is as Effective as Abciximab for Lowering ST-Segment ... - Apr 2, 2008 Funding for the study was provided by Merck & Co., Inc. In January of 2008, Iroko Pharmaceuticals acquired all non-US rights to Aggrastat from Merck. DG News Medicure Announces Corporate Restructuring - Mar 5, 2008 The Company's near term focus will be on its commercial asset AGGRASTAT(R) and the development of MC-1 for chronic cardiovascular and metabolic disease. FOXBusiness Failed drug trial wallops Medicure - Feb 26, 2008 At the same time, Medicure has another commercialized heart drug in its portfolio called Aggrastat, which it has the rights to sell in the United States. Globe and Mail, Medicure still 'focused on our core objective' after heart drug ... - Feb 25, 2008 The company also has "a proven cardiovascular commercial asset" in its Aggrastat drug for diabetics with heart problems. Additionally, the end of the MC-1 The Canadian Press UPDATE 1-Medicure slumps on drug trial disappointment - Feb 25, 2008 ...said the decision to scrap the MC-1 development leaves the company with little in its pipeline other than its Aggrastat acute coronary syndrome drug. Reuters Martin Cash - Feb 28, 2008 ...to manage the development of the chemistry, the management of the trials as well as the pharmaceutical sales force for its US heart drug, Aggrastat. Winnipeg Free Press, Market Report -- Short Stories (MCU) - Feb 25, 2008 The firm says even if they assign a 1x multiple on Aggrastat sales and add the cash, they only get to a $0.10 per share value. Briefing.com is the leading MSN Money Brand Names/Synonyms: Aggrastat is also known by the following brand names and/or synonyms: AGG; Aggrastat; Tirofiban; Tirofiban [Ban:Inn] Drug Category: Aggrastat is categorized under the following by the FDA: Fibrinolytic Agents; Platelet Aggregation Inhibitors; ATC:B01AC17 Dosage Forms: LIQUID; SOLUTION Absorption: Not Available Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 2-butylsulfonylamino-3-[4-[4-(4-piperidyl)butoxy]phenyl]-propanoic acid |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |
